New comprehensive report on pediatric long COVID symptoms published

Up to 5.8 million children and youth in the U.S. have experienced symptoms of COVID-19 that persisted long after initial infection.

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus using a propensity-score matched cohort.

July 17, 2024

Pharmalittle: Rite Aid files for bankruptcy; Alzheimer’s brain scans get broader Medicare coverage

Good morning, everyone, and welcome to another working week. We hope the weekend respite was sufficiently relaxing and invigorating, because that oh-so-familiar routine of online

October 16, 2023

Could Niacin Actually Induce Heart Disease?

Niacin metabolism was associated with incident major adverse cardiovascular events (MACE) and may be linked to the pathogenesis of heart disease via inflammatory pathways, researchers

February 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.